Stoke Therapeutics
STOK
53 hedge funds and large institutions have $339M invested in Stoke Therapeutics in 2019 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 13 increasing their positions, 9 reducing their positions, and 19 closing their positions.
44% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 9
32% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 19
13% more funds holding
Funds holding: 47 → 53 (+6)
3.46% more ownership
Funds ownership: 45.24% → 48.7% (+3.5%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
17% less capital invested
Capital invested by funds: $409M → $339M (-$70.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$20.8M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$16M |
| 3 |
BlackRock
New York
|
+$16M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$12.9M |
| 5 |
Millennium Management
New York
|
+$4.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$7.29M |
| 2 |
AI
Atom Investors
Austin,
Texas
|
-$5.82M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.77M |
| 4 |
O
OrbiMed
New York
|
-$3.79M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$2.91M |
STOK Hedge Fund Activity: Q3 2019 in Review
53 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Stoke Therapeutics (STOK) for Q3 2019, worth a combined $339M — down 17% from $409M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new STOK positions and 19 closed out — a net gain of 6 holders — while 13 added to existing stakes and 9 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $20.8M. The largest seller was Wellington Management Group, cutting an estimated $7.29M.
- 53 institutional investors held Stoke Therapeutics (STOK) as of Q3 2019, up from 47 in Q2 2019.
- Funds reported $339M of Stoke Therapeutics stock for Q3 2019, down 17% quarter-over-quarter.
- 25 funds opened new Stoke Therapeutics positions in Q3 2019 and 19 closed out, a net change of +6 holders.
- The largest Stoke Therapeutics buyer in Q3 2019 was Janus Henderson Group, an estimated $20.8M added.
- The largest Stoke Therapeutics seller in Q3 2019 was Wellington Management Group, an estimated $7.29M sold.
Based on aggregated 13F filings for Q3 2019.